All In MedTech

Device Trial Radar · NCT06271408

Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

Xenon Xe 129 Hyperpolarized MRI Ventilation Imaging for the Evaluation of Treatment Response Comparing Three Different Bronchodilator Aerosol Delivery Methods in Patients With COPD: A Pilot Study

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Mar 19, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Polarean, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Aerogen
First posted
Feb 21, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare responses to bronchodilator treatment delivered by three different aerosol delivery methods in patients with chronic obstructive pulmonary disease (COPD). The main question it aims to answer is whether there are differences in lung ventilation following treatment with each of the three methods as measured using hyperpolarized Xe 129 with MRI. Participants will: Receive a standard dose of albuterol delivered using each of 3 aerosol delivery devices. In total, participants will receive three treatments separated by at least 1 week each. Following each treatment, participants will have inhale an MRI contrast agent called hyperpolarized Xe 129 and will have images of their lungs taken with an MRI. Researchers will compare the different lung images taken after each treatment to see if there are differences in the distribution of air in the lungs (known as ventilation).

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation SolutionDrug

    Aerosolized albuterol

  • Vibrating Mesh NebulizerDevice

    A vibrating mesh nebulizer will be used to deliver aerosolized albuterol

  • Metered Dose InhalerDevice

    A metered dose inhaler will be used to deliver aerosolized albuterol

  • Jet NebulizerDevice

    A jet nebulizer will be used to deliver aerosolized albuterol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ventilation Defect PercentTime frame: measured immediately postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Virginia Sheridan Snyder Translational Fontaine Research Unit

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.